Home > Insider Trading > Filing (0000899243-23-002666)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1745999	Beam Therapeutics Inc.	BEAM	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1786484	Terry-Ann Burrell	C/O Beam Therapeutics Inc., 238 Main Street Cambridge MA 02142	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2023-01-23	5,426	$13.68	36,703	No	4	M	Direct
Common Stock	Disposition	2023-01-23	5,426	$45.02	31,277	No	4	S	Direct
Common Stock	Acquisiton	2023-01-24	14,810	$13.68	46,087	No	4	M	Direct
Common Stock	Disposition	2023-01-24	14,810	$45.01	31,277	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2023-01-23	5,426	$0.00	5,426	$13.68
Common Stock	Stock Option (Right to Buy)	Disposition	2023-01-24	14,810	$0.00	14,810	$13.68

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
237,629		2029-08-31	No	4	M	Direct
222,819		2029-08-31	No	4	M	Direct

Footnotes

The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.18, inclusive. The Reporting Person undertakes to provide Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.10, inclusive. The Reporting Person undertakes to provide BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The option vested as to 25% on the first anniversary of the of the vesting commencement date, August 20, 2019, and continues to vest at a rate of 2.78% each month thereafter until the option is fully vested.